COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells
Latest Information Update: 18 Mar 2022
At a glance
- Drugs PSC-04 (Primary)
- Indications Adult respiratory distress syndrome; COVID-19 respiratory infection; Respiratory insufficiency
- Focus Adverse reactions
- Acronyms CoronaStem1
- Sponsors Personalized Stem Cells; Sorrento Therapeutics
- 15 Mar 2022 Status changed from active, no longer recruiting to completed.
- 20 Apr 2021 According to a Sorrento Therapeutics media release, the company will be working with the FDA in the near future once the full dataset is available to plan a placebo-controlled pivotal study to support an emergency use authorization (EUA) submission.
- 20 Apr 2021 Planned number of patients changed from 20 to 10, according to a Sorrento Therapeutics media release.